Notification That Quarterly Report Will Be Submitted Late (nt 10-q)
August 15 2022 - 2:33PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 12b-25
Commission File Number: 333-191083
NOTIFICATION OF LATE FILING
☐ Form 10-K |
☐ Form 20-F |
☐ Form 11-K |
☒ Form 10-Q |
☐ Form 10-D |
☐ Form N-SAR |
☐ Form N-CSR |
|
For Period Ended: June 30, 2022
☐ Transition Report on Form 10-K |
☐ Transition Report on Form 10-Q |
☐ Transition Report on Form 20-F |
☐ Transition Report on Form N-SAR |
☐ Transition Report on Form 11-K |
|
For the Transition Period Ended: _______________________________________
Nothing in this form shall
be construed to imply that the Commission has verified any information contained herein.
If the notification relates
to a portion of the filing checked above, identify the Item(s) to which the notification relates: _______________________________________
PART I
REGISTRANT INFORMATION
Full name of registrant |
Rasna Therapeutics, Inc. |
Former name if applicable |
|
Address of principal executive office |
5 Penn Plaza, 19th Floor |
City, state and zip code |
New York, NY 10001 |
PART II
RULE 12b-25 (b) AND (c)
If the subject report could
not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25 (b), the following should
be completed. (Check box if appropriate.)
|
(a) |
The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense; |
☒ |
(b) |
The subject annual report, semi-annual report, transition report on Form 10-K, 20-F, 11-K or Form N-SAR or Form N-CSR, or portion thereof will be filed on or before the 15th calendar day following the prescribed due date or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and |
|
(c) |
The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable. |
PART III
NARRATIVE
State below in reasonable
detail the reasons why Form 10-K, 11-K, 20-F, 10-Q, N-SAR, N-CSR, or the transition report portion thereof, could not be filed within
the prescribed time period.
The compilation, dissemination
and review of the information required to be presented in the Form 10-Q for the relevant fiscal quarter has imposed time constraints that
have rendered timely filing of the Form 10-Q impracticable without undue hardship and expense to the registrant. The registrant undertakes
the responsibility to file such annual report no later than 5 days after its original due date.
PART
IV
OTHER
INFORMATION
(1) Name and telephone number of person to contact in regard to this
notification
Keeren Shah |
|
(646) |
|
396-4087 |
(Name) |
|
(Area Code) |
|
(Telephone Number) |
(2) Have all other periodic reports required under
Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12
months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s).
☒ Yes ☐ No
(3) Is it anticipated that any significant change
in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included
in the subject report or portion thereof?
☐ Yes ☒ No
If so: attach an explanation of the anticipated
change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be
made.
Rasna Therapeutics, Inc.
(Name of Registrant as Specified in Charter)
Has caused this notification to be signed on its
behalf by the undersigned thereunto duly authorized.
Dated: August 15, 2022 |
|
/s/ Keeren Shah |
|
By: |
Keeren Shah |
|
Title: |
Finance Director |
Actavia Life Sciences (CE) (USOTC:RASP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Actavia Life Sciences (CE) (USOTC:RASP)
Historical Stock Chart
From Sep 2023 to Sep 2024